|Bid||218.02 x 800|
|Ask||218.99 x 800|
|Day's range||212.22 - 218.60|
|52-week range||200.32 - 280.72|
|Beta (5Y monthly)||1.06|
|PE ratio (TTM)||15.53|
|Forward dividend & yield||2.88 (1.32%)|
|Ex-dividend date||22 Feb 2023|
|1y target est||N/A|
BOSTON, February 22, 2023--Ovia Health, a trusted digital health platform for women and families, today announced the expansion of its Ovia® app, which will now allow women to track menopause symptoms and access valuable resources and support to address the transition to menopause/perimenopause. The technology is available through Ovia’s consumer application and enterprise offerings for employers and health plans.
BURLINGTON, N.C., February 16, 2023--Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the fourth quarter and year ended Dec. 31, 2022, full-year 2023 guidance.
BURLINGTON, N.C., February 09, 2023--Labcorp (NYSE: LH), a leading global life sciences company, today announced that the new company to be formed by the planned spin-off of its Clinical Development business will be known as Fortrea. Upon completion of the spin-off from Labcorp, Fortrea will operate as an independent, publicly traded global CRO that offers comprehensive drug and medical device development services. With over 19,000 people, Fortrea will provide Phase I through IV clinical trial m